Email Us
View Reports

Global Anti-diabetic Drugs Market Analysis and Forecast 2016-2024 | Industry Growth Opportunities

  • ID : 8277030  |  
  • Published : Jan-2018  |  
  • Region : Global  |  
  • Pages : 260   |  
  • Publisher : Goldstein Research

Global Antidiabetic Drugs Market

Market Overview

Antidiabetic drugs do not cure diabetes instead they help diabetic patients to keep their condition under control and lower the risk of diabetes complications in future. Type 2 diabetes and other non-communicable diseases are a major public health concern globally with 6.4% of the adult’s population i.e. 285 million people are suffering from diabetes, which is projected to reach the number 552 million by 2030, according to the International Diabetes Federation. In US alone approximating 79 million individuals are reported prediabetic. Most of the diabetic population prefers generic drugs rather than the branded ones, for instance, most people take metformin, not Glucophage, and similarly many take glipizide, a generic sulfonylurea drug, while few take Glucotrol, its brand-name version.

Goldstein Research analyst forecast that antidiabetic drugs market size is set to reach USD 106.5 billion by 2024, at a CAGR of 10.12% over the forecast years.

Covered In This Global Antidiabetic Drugs Market Report

The report covers the present ground scenario and the future growth prospects of the Antidiabetic Drugs market for 2016-2024 along with the number of diabetic population and adoption rate of generic as well as branded drugs. We calculated the market size and revenue share on the basis of revenue generated from the sales of Antidiabetic Drugs from major players and number of total diabetic patients across the globe.

Global Antidiabetic Drugs - Market Segmentation

By Drug Class

 Biguanides (metformin)

 Sulfonylureas (glimepiride)

 Meglitinides (repaglinide)

 Thiazolidinediones (pioglitazone)

 Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin)

 α-Glucosidase inhibitors (acarbose)

By Mode of Administration

 Oral (eg. oral hypoglycemic)

 Intravenously (eg. insulin and GLP-1 receptor agonists)

By Diabetes Type

 Diabetes Type 1

 Diabetes Type 2

 Other Types

o Genetic defects of the β-cell

o Genetic defects in insulin action

o Endocrinopathies

o Drug- or chemical-induced diabetes

o Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)

By Drug Type

 Generic

 Branded

Based on Geography

 North America (U.S. & Canada) Antidiabetic Drugs Market

 Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Antidiabetic Drugs Market

 Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) Antidiabetic Drugs Market

 Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) Antidiabetic Drugs Market

 Middle East & Africa (GCC, South Africa, North Africa, RoMEA) Antidiabetic Drugs Market

On the basis of drug type, branded drugs dominate the antidiabetic drugs market by acquiring 51% of total market share while in future generic drugs tends to hold the promising market .

Antidiabetic Drugs Market Outlook 2016-2024, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the global antidiabetic drugs market. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. Global market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.

Our global antidiabetic drugs market report comprises of the following companies as the key players in the Antidiabetic Drugs market: Zydus Cadila, Actavis, Alphapharm, Andromeda Biotech, Arisaph, Astellas Pharma, AstraZeneca, Bayer, Biocon, Blue Cross, Bristol-Myers Squibb, Biogen Idec, Boehringer Ingelheim, Boston Therapeutics.

Other high-flying vendors in the market are Eli Lilly, Franco-Indian Pharmaceuticals, Furiex Pharmaceuticals, Genentech, Generex Biotechnology Corporation, GlaxoSmithKline (GSK), Johnson & Johnson (J&J), Lupin, Merck & Co., Mylan, Novartis, Novo Nordisk, Pfizer, Ranbaxy Laboratories, Roche, Sanofi, Sun Pharma.

According to our global market study on the basis of extensive primary and secondary research: “One of the growing trend of antidiabetic drugs market is that CRO (Contract Research Organizations) and CMO (Contract Manufacturing Organization) sectors saw dozens of acquisitions in 2016 and 2017, and expect that trend to continue in 2018.”

According to the report, major driver for expansion of Antidiabetic Drugs market is strong encouragement from the governments like promoting healthy nutritional policies and favoring modifications in the environment that encourage greater physical activity and make prevention affordable for all citizens at high risk are the drivers of antidiabetic drug market.

Further, the report states that one challenge in antidiabetic drug market is despite the availability of numerous branded antidiabetic drugs, maximum of them have lost patent protection and due to huge pressures from government and regulatory authorities, to ban top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients.

Based on geography, North America holds the largest market share of 35% in 2016 while APAC is projected to witness a robust growth with a CAGR of 11.12% over the forecast years. Middle East and Africa hold the opportunities for the antidiabetic drugs player owing to consumer spending capacity and rising irregular dietary habits leading to increasing occurrences of diabetes and related disorders

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For a full detailed overview, send us the sample request.

Key questions answered in this Antidiabetic Drugs report

• What is the total market size by 2024 and what would be the expected growth rate of air data system?

• What is the sale of Antidiabetic Drugs in 2015-16 and what would be the expected demand over the forecast period?

• What are the key market trends?

• What are the factors which are driving this market?

• What are the major barriers to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities for the existing and entry level players?

• What are the recent developments and business strategy of the key players?

We can provide two hour complimentary interaction with our analyst after the purchase of this market report. Details are imparted within the report.

Table of Contents

1. Executive Summary

2. Research Methodology

3. Regional Opportunity Analysis on the basis of Competitors

4. Global Antidiabetic DrugsMarket Size (USD Billion) and Forecast Analysis, 2016-2024

5. Market Dynamics: Growth Drivers, Restraints and Opportunities

5.1. Risk Factors

5.2. Regional Variations

5.3. Recent Trends and Developments

6. Global Antidiabetic DrugsMarket Segmentation

6.1. Antidiabetic DrugsMarketBy Drug Class (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.1.1. Adoption Rate (%) of Antidiabetic DrugsMarket by Drug Class

6.1.2. Biguanides (metformin)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.1.3. Sulfonylureas (glimepiride)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.1.4. Meglitinides (repaglinide)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.1.5. Thiazolidinediones (pioglitazone)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.1.6. Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.1.7. α-Glucosidase inhibitors (acarbose) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.1.8. Market Attractiveness of Antidiabetic DrugsMarket by Drug Class

6.1.9. BPS Analysis of Antidiabetic DrugsMarket by Drug Class

6.2. Antidiabetic Drugs Market By Mode of Administration (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.2.1. Adoption Rate (%) of Antidiabetic Drugs Market by Mode of Administration

6.2.2. Oral (eg. oral hypoglycemic) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.2.3. Intravenously (eg. insulin and GLP-1 receptor agonists) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.2.4. Market Attractiveness of Antidiabetic Drugs Market by Mode of Administration

6.2.5. BPS Analysis of Antidiabetic Drugs Market by Mode of Administration

6.3. Antidiabetic DrugsMarket By Diabetes Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.1. Adoption Rate (%) of Antidiabetic Drugs Market by Diabetes Type

6.3.2. Diabetes Type 1 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.3. Diabetes Type 2 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.4. Other Types(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.4.1. Genetic defects of the β-cell(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.4.2. Genetic defects in insulin action(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.4.3. Endocrinopathies(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.4.4. Drug- or chemical-induced diabetes(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.4.5. Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.3.5. Market Attractiveness of Antidiabetic Drugs Market by Diabetes Type

6.3.6. BPS Analysis of Antidiabetic Drugs Market by Diabetes Type

6.4. Antidiabetic DrugsMarket By Drug Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.4.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Type

6.4.2. Generic Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.4.3. Branded Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.4.4. Market Attractiveness of Antidiabetic Drugs Market by Drug Type

6.4.5. BPS Analysis of Antidiabetic Drugs Market by Drug Type

6.5. Antidiabetic DrugsMarket By Region (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024)

6.5.1. North America Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.1. North America Antidiabetic DrugsMarket By Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024)

6.5.1.1.1. U.S. Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.1.2. Canada Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.1.3. Market Attractiveness of Antidiabetic DrugsMarket by Country

6.5.1.1.4. BPS Analysis of Antidiabetic DrugsMarket by Country

6.5.1.2. North America Antidiabetic Drugs Market By Drug Class (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.2.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Class

6.5.1.2.2. Biguanides (metformin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.2.3. Sulfonylureas (glimepiride) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.2.4. Meglitinides (repaglinide) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.2.5. Thiazolidinediones (pioglitazone) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.2.6. Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.2.7. α-Glucosidase inhibitors (acarbose) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.2.8. Market Attractiveness of Antidiabetic Drugs Market by Drug Class

6.5.1.2.9. BPS Analysis of Antidiabetic Drugs Market by Drug Class

6.5.1.3. North America Antidiabetic Drugs Market By Mode of Administration (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.3.1. Adoption Rate (%) of Antidiabetic Drugs Market by Mode of Administration

6.5.1.3.2. Oral (eg. oral hypoglycemic) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.3.3. Intravenously (eg. insulin and GLP-1 receptor agonists) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.3.4. Market Attractiveness of Antidiabetic Drugs Market by Mode of Administration

6.5.1.3.5. BPS Analysis of Antidiabetic Drugs Market by Mode of Administration

6.5.1.4. North America Antidiabetic Drugs Market By Diabetes Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.1. Adoption Rate (%) of Antidiabetic Drugs Market by Diabetes Type

6.5.1.4.2. Diabetes Type 1 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.3. Diabetes Type 2 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.4. Other Types (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.4.1. Genetic defects of the β-cell(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.4.2. Genetic defects in insulin action(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.4.3. Endocrinopathies(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.4.4. Drug- or chemical-induced diabetes(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.4.5. Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.4.5. Market Attractiveness of Antidiabetic Drugs Market by Diabetes Type

6.5.1.4.6. BPS Analysis of Antidiabetic Drugs Market by Diabetes Type

6.5.1.5. North America Antidiabetic Drugs Market By Drug Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.5.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Type

6.5.1.5.2. Generic Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.5.3. Branded Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.1.5.4. Market Attractiveness of Antidiabetic Drugs Market by Drug Type

6.5.1.5.5. BPS Analysis of Antidiabetic Drugs Market by Drug Type

6.5.2. Europe Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1. Europe Antidiabetic Drugs MarketBy Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024)

6.5.2.1.1. UK Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.2. France Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.3. Italy Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.4. Germany Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.5. Spain Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.6. Hungary Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.7. Sweden Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.8. Russia Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.9. Poland Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.10. Rest of EuropeAntidiabetic Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.1.11. Market Attractiveness of Antidiabetic DrugsMarket by Country

6.5.2.1.12. BPS Analysis of Antidiabetic DrugsMarket by Country

6.5.2.2. Europe Antidiabetic Drugs Market By Drug Class (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.2.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Class

6.5.2.2.2. Biguanides (metformin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.2.3. Sulfonylureas (glimepiride) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.2.4. Meglitinides (repaglinide) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.2.5. Thiazolidinediones (pioglitazone) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.2.6. Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.2.7. α-Glucosidase inhibitors (acarbose) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.2.8. Market Attractiveness of Antidiabetic Drugs Market by Drug Class

6.5.2.2.9. BPS Analysis of Antidiabetic Drugs Market by Drug Class

6.5.2.3. Europe Antidiabetic Drugs Market By Mode of Administration (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.3.1. Adoption Rate (%) of Antidiabetic Drugs Market by Mode of Administration

6.5.2.3.2. Oral (eg. oral hypoglycemic) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.3.3. Intravenously (eg. insulin and GLP-1 receptor agonists) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.3.4. Market Attractiveness of Antidiabetic Drugs Market by Mode of Administration

6.5.2.3.5. BPS Analysis of Antidiabetic Drugs Market by Mode of Administration

6.5.2.4. Europe Antidiabetic Drugs Market By Diabetes Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.1. Adoption Rate (%) of Antidiabetic Drugs Market by Diabetes Type

6.5.2.4.2. Diabetes Type 1 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.3. Diabetes Type 2 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.4. Other Types (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.4.1. Genetic defects of the β-cell(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.4.2. Genetic defects in insulin action(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.4.3. Endocrinopathies(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.4.4. Drug- or chemical-induced diabetes(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.4.5. Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.4.5. Market Attractiveness of Antidiabetic Drugs Market by Diabetes Type

6.5.2.4.6. BPS Analysis of Antidiabetic Drugs Market by Diabetes Type

6.5.2.5. Europe Antidiabetic Drugs Market By Drug Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.5.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Type

6.5.2.5.2. Generic Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.5.3. Branded Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.2.5.4. Market Attractiveness of Antidiabetic Drugs Market by Drug Type

6.5.2.5.5. BPS Analysis of Antidiabetic Drugs Market by Drug Type

6.5.3. Latin AmericaAntidiabetic Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.1. Latin America Antidiabetic DrugsBy Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024)

6.5.3.1.1. Brazil Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.1.2. Mexico Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.1.3. Rest of Latin America Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.1.4. Market Attractiveness of Antidiabetic DrugsMarket by Country

6.5.3.1.5. BPS Analysis of Antidiabetic DrugsMarket by Country

6.5.3.2. Latin America Antidiabetic Drugs Market By Drug Class (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.2.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Class

6.5.3.2.2. Biguanides (metformin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.2.3. Sulfonylureas (glimepiride) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.2.4. Meglitinides (repaglinide) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.2.5. Thiazolidinediones (pioglitazone) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.2.6. Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.2.7. α-Glucosidase inhibitors (acarbose) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.2.8. Market Attractiveness of Antidiabetic Drugs Market by Drug Class

6.5.3.2.9. BPS Analysis of Antidiabetic Drugs Market by Drug Class

6.5.3.3. Latin America Antidiabetic Drugs Market By Mode of Administration (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.3.1. Adoption Rate (%) of Antidiabetic Drugs Market by Mode of Administration

6.5.3.3.2. Oral (eg. oral hypoglycemic) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.3.3. Intravenously (eg. insulin and GLP-1 receptor agonists) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.3.4. Market Attractiveness of Antidiabetic Drugs Market by Mode of Administration

6.5.3.3.5. BPS Analysis of Antidiabetic Drugs Market by Mode of Administration

6.5.3.4. Latin America Antidiabetic Drugs Market By Diabetes Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.1. Adoption Rate (%) of Antidiabetic Drugs Market by Diabetes Type

6.5.3.4.2. Diabetes Type 1 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.3. Diabetes Type 2 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.4. Other Types (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.4.1. Genetic defects of the β-cell(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.4.2. Genetic defects in insulin action(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.4.3. Endocrinopathies(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.4.4. Drug- or chemical-induced diabetes(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.4.5. Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.4.5. Market Attractiveness of Antidiabetic Drugs Market by Diabetes Type

6.5.3.4.6. BPS Analysis of Antidiabetic Drugs Market by Diabetes Type

6.5.3.5. Latin America Antidiabetic Drugs Market By Drug Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.5.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Type

6.5.3.5.2. Generic Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.5.3. Branded Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.3.5.4. Market Attractiveness of Antidiabetic Drugs Market by Drug Type

6.5.3.5.5. BPS Analysis of Antidiabetic Drugs Market by Drug Type

6.5.4. Asia Pacific (APAC) Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1. Asia Pacific Antidiabetic DrugsMarket By Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024)

6.5.4.1.1. China Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1.2. Japan Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1.3. India Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1.4. Singapore Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1.5. South Korea Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1.6. Australia Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1.7. New Zealand Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1.8. Rest of APAC Antidiabetic DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.1.9. Market Attractiveness of Antidiabetic DrugsMarket by Country

6.5.4.1.10. BPS Analysis of Antidiabetic DrugsMarket by Country

6.5.4.2. Asia Pacific (APAC)Antidiabetic Drugs Market By Drug Class (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.2.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Class

6.5.4.2.2. Biguanides (metformin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.2.3. Sulfonylureas (glimepiride) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.2.4. Meglitinides (repaglinide) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.2.5. Thiazolidinediones (pioglitazone) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.2.6. Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.2.7. α-Glucosidase inhibitors (acarbose) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.2.8. Market Attractiveness of Antidiabetic Drugs Market by Drug Class

6.5.4.2.9. BPS Analysis of Antidiabetic Drugs Market by Drug Class

6.5.4.3. Asia Pacific (APAC)Antidiabetic Drugs Market By Mode of Administration (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.3.1. Adoption Rate (%) of Antidiabetic Drugs Market by Mode of Administration

6.5.4.3.2. Oral (eg. oral hypoglycemic) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.3.3. Intravenously (eg. insulin and GLP-1 receptor agonists) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.3.4. Market Attractiveness of Antidiabetic Drugs Market by Mode of Administration

6.5.4.3.5. BPS Analysis of Antidiabetic Drugs Market by Mode of Administration

6.5.4.4. Asia Pacific (APAC)Antidiabetic Drugs Market By Diabetes Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.1. Adoption Rate (%) of Antidiabetic Drugs Market by Diabetes Type

6.5.4.4.2. Diabetes Type 1 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.3. Diabetes Type 2 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.4. Other Types (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.4.1. Genetic defects of the β-cell(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.4.2. Genetic defects in insulin action(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.4.3. Endocrinopathies(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.4.4. Drug- or chemical-induced diabetes(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.4.5. Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.4.5. Market Attractiveness of Antidiabetic Drugs Market by Diabetes Type

6.5.4.4.6. BPS Analysis of Antidiabetic Drugs Market by Diabetes Type

6.5.4.5. Asia Pacific (APAC)Antidiabetic Drugs Market By Drug Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.5.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Type

6.5.4.5.2. Generic Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.5.3. Branded Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.4.5.4. Market Attractiveness of Antidiabetic Drugs Market by Drug Type

6.5.4.5.5. BPS Analysis of Antidiabetic Drugs Market by Drug Type

6.5.5. Middle East & Africa Antidiabetic Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.1. Middle East & Africa Antidiabetic Drugs Market By Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024)

6.5.5.1.1. Gulf Cooperation Council Countries (GCC) Antidiabetic Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.1.2. South Africa Antidiabetic Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.1.3. North Africa Antidiabetic Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.1.4. Rest of Middle East and Africa Antidiabetic Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.1.5. Market Attractiveness of Antidiabetic Drugs Market by Country

6.5.5.1.6. BPS Analysis of Antidiabetic Drugs Market by Country

6.5.5.2. Middle East & AfricaAntidiabetic Drugs Market By Drug Class (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.2.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Class

6.5.5.2.2. Biguanides (metformin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.2.3. Sulfonylureas (glimepiride) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.2.4. Meglitinides (repaglinide) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.2.5. Thiazolidinediones (pioglitazone) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.2.6. Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.2.7. α-Glucosidase inhibitors (acarbose) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.2.8. Market Attractiveness of Antidiabetic Drugs Market by Drug Class

6.5.5.2.9. BPS Analysis of Antidiabetic Drugs Market by Drug Class

6.5.5.3. Middle East & AfricaAntidiabetic Drugs Market By Mode of Administration (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.3.1. Adoption Rate (%) of Antidiabetic Drugs Market by Mode of Administration

6.5.5.3.2. Oral (eg. oral hypoglycemic) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.3.3. Intravenously (eg. insulin and GLP-1 receptor agonists) (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.3.4. Market Attractiveness of Antidiabetic Drugs Market by Mode of Administration

6.5.5.3.5. BPS Analysis of Antidiabetic Drugs Market by Mode of Administration

6.5.5.4. Middle East & AfricaAntidiabetic Drugs Market By Diabetes Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.1. Adoption Rate (%) of Antidiabetic Drugs Market by Diabetes Type

6.5.5.4.2. Diabetes Type 1 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.3. Diabetes Type 2 (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.4. Other Types (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.4.1. Genetic defects of the β-cell(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.4.2. Genetic defects in insulin action(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.4.3. Endocrinopathies(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.4.4. Drug- or chemical-induced diabetes(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.4.5. Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)(Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.4.5. Market Attractiveness of Antidiabetic Drugs Market by Diabetes Type

6.5.5.4.6. BPS Analysis of Antidiabetic Drugs Market by Diabetes Type

6.5.5.5. Asia Pacific (APAC)Antidiabetic Drugs Market By Drug Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.5.1. Adoption Rate (%) of Antidiabetic Drugs Market by Drug Type

6.5.5.5.2. Generic Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.5.3. Branded Drug (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024)

6.5.5.5.4. Market Attractiveness of Antidiabetic Drugs Market by Drug Type

6.5.5.5.5. BPS Analysis of Antidiabetic Drugs Market by Drug Type

7. Competitive Outlook

7.1. Market Share of Major Players (2016)

7.2. Company Profiles

7.2.1. ZydusCadila

7.2.1.1. Company Synopsis

7.2.1.2. Business Strategy

7.2.1.3. Product Portfolio

7.2.1.4. SWOT Analysis

7.3. Actavis

7.4. Alphapharm

7.5. Andromeda Biotech

7.6. Arisaph

7.7. Astellas Pharma

7.8. AstraZeneca

7.9. Bayer

7.10. Biocon

7.11. Blue Cross

7.12. Bristol-Myers Squibb

7.13. Biogen Idec

7.14. BoehringerIngelheim

7.15. Boston Therapeutics

7.16. Eli Lilly

7.17. Franco-Indian Pharmaceuticals

7.18. Furiex Pharmaceuticals

7.19. Genentech

7.20. Generex Biotechnology Corporation

7.21. GlaxoSmithKline (GSK)

7.22. Johnson & Johnson (J&J)

7.23. Lupin

7.24. Merck & Co.

7.25. Mylan

7.26. Novartis

7.27. Novo Nordisk

7.28. Pfizer

7.29. Ranbaxy Laboratories

7.30. Roche

7.31. Sanofi

7.32. Sun Pharma

8. Porter’s Five Force Model

9. Market Landscape: Competition and Beyond

10. Market outlook for business players and entry level players to ascertain their business in dynamic ecosystem

11. Expert Analysis

12. Concluding Remarks

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?